Collectively, the encouraging results obtained with IFN-α-2b in COVID-19 patients in China, together with the complete absence of IFN-β release, the greater sensitivity of SARS-CoV-2 to IFN-β in vitro and the fact that auto-antibodies against IFN-β appear to be rare in severe COVID-19 patients gave a reason for hope regarding superior clinical efficacy of inhaled IFN-β. This evidence concerns the gene IFNB1 and COVID-19.